Answers are grounded in this paper and cite their sources.
CD8 T cells constitute one of the pillars of the adaptive immune response. They play a key role in eliminating pathogen-infected and cancerous cells. To effectively carry out their function, naïve CD8 T cells must undergo priming/activation in which several cell types, receptors, cytokines, and chemokines are involved. Various therapeutic approaches, such as vaccinations and anti-cancer therapies, i.e., immune checkpoint blockade (ICB) and Chimeric Antigen Receptor (CAR) T cell transfer, attempt to harness CD8 T cell biology to protect from or treat life-threatening diseases. Despite the significant success of CD8-T-cell-related therapies, the overall response rate of cancer patients remains relatively low, perhaps due to an incomplete understanding of the crucial events leading to optimal CD8 T cell activation. Recent findings highlight the importance of CD4 T cell help in CD8 T cell priming as well as the existence of an additional priming phase for the selection and expansion of high affinity T cells. Together, these findings offer a refined conceptual framework to guide future research and therapeutic development. Here, we present a revised perspective on clinically relevant CD8 T cell–based therapies in light of recent discoveries.
No takes yet. Share an insight, caveat, or question.
Jobin et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: